nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—RPS6KB1—obesity	0.407	1	CbGaD
Bosutinib—Bronchitis—Sibutramine—obesity	0.000436	0.00281	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Orlistat—obesity	0.000435	0.00281	CcSEcCtD
Bosutinib—Dehydration—Bupropion—obesity	0.000425	0.00274	CcSEcCtD
Bosutinib—Nausea—Phendimetrazine—obesity	0.000423	0.00273	CcSEcCtD
Bosutinib—Asthenia—Phentermine—obesity	0.000418	0.0027	CcSEcCtD
Bosutinib—Feeling abnormal—Diethylpropion—obesity	0.000417	0.00269	CcSEcCtD
Bosutinib—Infestation NOS—Orlistat—obesity	0.000417	0.00269	CcSEcCtD
Bosutinib—Infestation—Orlistat—obesity	0.000417	0.00269	CcSEcCtD
Bosutinib—Abdominal pain upper—Bupropion—obesity	0.000417	0.00269	CcSEcCtD
Bosutinib—Fatigue—Cimetidine—obesity	0.000416	0.00268	CcSEcCtD
Bosutinib—Renal failure—Orlistat—obesity	0.00041	0.00265	CcSEcCtD
Bosutinib—Nasopharyngitis—Bupropion—obesity	0.000408	0.00264	CcSEcCtD
Bosutinib—Pneumonia—Sibutramine—obesity	0.000406	0.00262	CcSEcCtD
Bosutinib—Gastritis—Bupropion—obesity	0.000404	0.00261	CcSEcCtD
Bosutinib—Urticaria—Diethylpropion—obesity	0.000402	0.0026	CcSEcCtD
Bosutinib—Dizziness—Phenylpropanolamine—obesity	0.000402	0.0026	CcSEcCtD
Bosutinib—Diarrhoea—Phentermine—obesity	0.000398	0.00257	CcSEcCtD
Bosutinib—Feeling abnormal—Cimetidine—obesity	0.000397	0.00256	CcSEcCtD
Bosutinib—Renal failure—Sibutramine—obesity	0.000397	0.00256	CcSEcCtD
Bosutinib—Influenza—Bupropion—obesity	0.000395	0.00255	CcSEcCtD
Bosutinib—Hepatobiliary disease—Orlistat—obesity	0.000395	0.00255	CcSEcCtD
Bosutinib—Vomiting—Phenylpropanolamine—obesity	0.000387	0.0025	CcSEcCtD
Bosutinib—Dizziness—Phentermine—obesity	0.000385	0.00248	CcSEcCtD
Bosutinib—Rash—Phenylpropanolamine—obesity	0.000384	0.00248	CcSEcCtD
Bosutinib—Dermatitis—Phenylpropanolamine—obesity	0.000383	0.00247	CcSEcCtD
Bosutinib—Body temperature increased—Cimetidine—obesity	0.000381	0.00246	CcSEcCtD
Bosutinib—Fluid retention—Topiramate—obesity	0.000381	0.00246	CcSEcCtD
Bosutinib—Bronchitis—Bupropion—obesity	0.00038	0.00245	CcSEcCtD
Bosutinib—Abdominal discomfort—Bupropion—obesity	0.000378	0.00244	CcSEcCtD
Bosutinib—Pancytopenia—Bupropion—obesity	0.000375	0.00242	CcSEcCtD
Bosutinib—Hepatitis—Orlistat—obesity	0.000375	0.00242	CcSEcCtD
Bosutinib—Vomiting—Phentermine—obesity	0.00037	0.00239	CcSEcCtD
Bosutinib—Urinary tract disorder—Orlistat—obesity	0.00037	0.00239	CcSEcCtD
Bosutinib—Oedema peripheral—Orlistat—obesity	0.000369	0.00238	CcSEcCtD
Bosutinib—Urethral disorder—Orlistat—obesity	0.000367	0.00237	CcSEcCtD
Bosutinib—Rash—Phentermine—obesity	0.000367	0.00237	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Bupropion—obesity	0.000367	0.00237	CcSEcCtD
Bosutinib—Dermatitis—Phentermine—obesity	0.000367	0.00237	CcSEcCtD
Bosutinib—Headache—Phentermine—obesity	0.000365	0.00235	CcSEcCtD
Bosutinib—Rash maculo-papular—Topiramate—obesity	0.000364	0.00235	CcSEcCtD
Bosutinib—Nausea—Phenylpropanolamine—obesity	0.000361	0.00233	CcSEcCtD
Bosutinib—Oedema peripheral—Sibutramine—obesity	0.000357	0.0023	CcSEcCtD
Bosutinib—Pneumonia—Bupropion—obesity	0.000354	0.00228	CcSEcCtD
Bosutinib—Infestation—Bupropion—obesity	0.000352	0.00227	CcSEcCtD
Bosutinib—Infestation NOS—Bupropion—obesity	0.000352	0.00227	CcSEcCtD
Bosutinib—Diarrhoea—Diethylpropion—obesity	0.000347	0.00224	CcSEcCtD
Bosutinib—Nausea—Phentermine—obesity	0.000346	0.00223	CcSEcCtD
Bosutinib—Asthenia—Cimetidine—obesity	0.000346	0.00223	CcSEcCtD
Bosutinib—Immune system disorder—Orlistat—obesity	0.000338	0.00218	CcSEcCtD
Bosutinib—Tinnitus—Sibutramine—obesity	0.000338	0.00218	CcSEcCtD
Bosutinib—Mediastinal disorder—Orlistat—obesity	0.000338	0.00218	CcSEcCtD
Bosutinib—Dizziness—Diethylpropion—obesity	0.000335	0.00216	CcSEcCtD
Bosutinib—Diarrhoea—Cimetidine—obesity	0.00033	0.00213	CcSEcCtD
Bosutinib—Immune system disorder—Sibutramine—obesity	0.000327	0.00211	CcSEcCtD
Bosutinib—Malnutrition—Orlistat—obesity	0.000326	0.0021	CcSEcCtD
Bosutinib—Vomiting—Diethylpropion—obesity	0.000322	0.00208	CcSEcCtD
Bosutinib—Rash—Diethylpropion—obesity	0.000319	0.00206	CcSEcCtD
Bosutinib—Dysgeusia—Orlistat—obesity	0.000319	0.00206	CcSEcCtD
Bosutinib—Dermatitis—Diethylpropion—obesity	0.000319	0.00206	CcSEcCtD
Bosutinib—Dizziness—Cimetidine—obesity	0.000319	0.00206	CcSEcCtD
Bosutinib—Headache—Diethylpropion—obesity	0.000317	0.00205	CcSEcCtD
Bosutinib—Hepatitis—Bupropion—obesity	0.000316	0.00204	CcSEcCtD
Bosutinib—Malnutrition—Sibutramine—obesity	0.000316	0.00204	CcSEcCtD
Bosutinib—Back pain—Orlistat—obesity	0.000315	0.00203	CcSEcCtD
Bosutinib—Urinary tract disorder—Bupropion—obesity	0.000312	0.00201	CcSEcCtD
Bosutinib—Oedema peripheral—Bupropion—obesity	0.000311	0.00201	CcSEcCtD
Bosutinib—Connective tissue disorder—Bupropion—obesity	0.000311	0.002	CcSEcCtD
Bosutinib—Urethral disorder—Bupropion—obesity	0.00031	0.002	CcSEcCtD
Bosutinib—Dysgeusia—Sibutramine—obesity	0.000309	0.00199	CcSEcCtD
Bosutinib—Vomiting—Cimetidine—obesity	0.000306	0.00198	CcSEcCtD
Bosutinib—Back pain—Sibutramine—obesity	0.000305	0.00197	CcSEcCtD
Bosutinib—Rash—Cimetidine—obesity	0.000304	0.00196	CcSEcCtD
Bosutinib—Dermatitis—Cimetidine—obesity	0.000304	0.00196	CcSEcCtD
Bosutinib—Ill-defined disorder—Orlistat—obesity	0.000303	0.00195	CcSEcCtD
Bosutinib—Headache—Cimetidine—obesity	0.000302	0.00195	CcSEcCtD
Bosutinib—Nausea—Diethylpropion—obesity	0.000301	0.00194	CcSEcCtD
Bosutinib—Erythema multiforme—Bupropion—obesity	0.000299	0.00193	CcSEcCtD
Bosutinib—Tinnitus—Bupropion—obesity	0.000295	0.0019	CcSEcCtD
Bosutinib—Malaise—Orlistat—obesity	0.000294	0.0019	CcSEcCtD
Bosutinib—Cardiac disorder—Bupropion—obesity	0.000293	0.00189	CcSEcCtD
Bosutinib—Ill-defined disorder—Sibutramine—obesity	0.000293	0.00189	CcSEcCtD
Bosutinib—Anaemia—Sibutramine—obesity	0.000292	0.00188	CcSEcCtD
Bosutinib—Nausea—Cimetidine—obesity	0.000286	0.00185	CcSEcCtD
Bosutinib—Immune system disorder—Bupropion—obesity	0.000285	0.00184	CcSEcCtD
Bosutinib—Mediastinal disorder—Bupropion—obesity	0.000285	0.00184	CcSEcCtD
Bosutinib—Malaise—Sibutramine—obesity	0.000285	0.00184	CcSEcCtD
Bosutinib—Cough—Orlistat—obesity	0.000285	0.00184	CcSEcCtD
Bosutinib—Leukopenia—Sibutramine—obesity	0.000282	0.00182	CcSEcCtD
Bosutinib—Face oedema—Topiramate—obesity	0.000281	0.00181	CcSEcCtD
Bosutinib—Myalgia—Orlistat—obesity	0.000278	0.00179	CcSEcCtD
Bosutinib—Chest pain—Orlistat—obesity	0.000278	0.00179	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.000276	0.00178	CcSEcCtD
Bosutinib—Cough—Sibutramine—obesity	0.000275	0.00178	CcSEcCtD
Bosutinib—Malnutrition—Bupropion—obesity	0.000275	0.00177	CcSEcCtD
Bosutinib—Discomfort—Orlistat—obesity	0.000274	0.00177	CcSEcCtD
Bosutinib—Blood creatinine increased—Topiramate—obesity	0.000273	0.00176	CcSEcCtD
Bosutinib—Dehydration—Topiramate—obesity	0.000271	0.00175	CcSEcCtD
Bosutinib—Dysgeusia—Bupropion—obesity	0.000269	0.00174	CcSEcCtD
Bosutinib—Chest pain—Sibutramine—obesity	0.000269	0.00173	CcSEcCtD
Bosutinib—Arthralgia—Sibutramine—obesity	0.000269	0.00173	CcSEcCtD
Bosutinib—Myalgia—Sibutramine—obesity	0.000269	0.00173	CcSEcCtD
Bosutinib—Anaphylactic shock—Orlistat—obesity	0.000266	0.00172	CcSEcCtD
Bosutinib—Oedema—Orlistat—obesity	0.000266	0.00172	CcSEcCtD
Bosutinib—Back pain—Bupropion—obesity	0.000266	0.00172	CcSEcCtD
Bosutinib—Abdominal pain upper—Topiramate—obesity	0.000266	0.00171	CcSEcCtD
Bosutinib—Discomfort—Sibutramine—obesity	0.000265	0.00171	CcSEcCtD
Bosutinib—Infection—Orlistat—obesity	0.000264	0.00171	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Topiramate—obesity	0.000262	0.00169	CcSEcCtD
Bosutinib—Nervous system disorder—Orlistat—obesity	0.000261	0.00168	CcSEcCtD
Bosutinib—Nasopharyngitis—Topiramate—obesity	0.00026	0.00168	CcSEcCtD
Bosutinib—Skin disorder—Orlistat—obesity	0.000258	0.00167	CcSEcCtD
Bosutinib—Gastritis—Topiramate—obesity	0.000258	0.00166	CcSEcCtD
Bosutinib—Oedema—Sibutramine—obesity	0.000258	0.00166	CcSEcCtD
Bosutinib—Anaphylactic shock—Sibutramine—obesity	0.000258	0.00166	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Topiramate—obesity	0.000257	0.00166	CcSEcCtD
Bosutinib—Infection—Sibutramine—obesity	0.000256	0.00165	CcSEcCtD
Bosutinib—Ill-defined disorder—Bupropion—obesity	0.000255	0.00165	CcSEcCtD
Bosutinib—Anaemia—Bupropion—obesity	0.000254	0.00164	CcSEcCtD
Bosutinib—Thrombocytopenia—Sibutramine—obesity	0.000252	0.00163	CcSEcCtD
Bosutinib—SIK1—pituitary gland—obesity	0.000252	0.00149	CbGeAlD
Bosutinib—IRAK4—pituitary gland—obesity	0.000252	0.00149	CbGeAlD
Bosutinib—SIK1—adipose tissue—obesity	0.000251	0.00149	CbGeAlD
Bosutinib—IRAK4—adipose tissue—obesity	0.000251	0.00149	CbGeAlD
Bosutinib—TNK2—endocrine gland—obesity	0.00025	0.00148	CbGeAlD
Bosutinib—Skin disorder—Sibutramine—obesity	0.00025	0.00161	CcSEcCtD
Bosutinib—STK35—adrenal gland—obesity	0.00025	0.00148	CbGeAlD
Bosutinib—MAP2K1—adrenal gland—obesity	0.00025	0.00148	CbGeAlD
Bosutinib—EPHA4—pituitary gland—obesity	0.00025	0.00148	CbGeAlD
Bosutinib—EPHA4—adipose tissue—obesity	0.000249	0.00147	CbGeAlD
Bosutinib—CSK—adrenal gland—obesity	0.000248	0.00147	CbGeAlD
Bosutinib—STK4—liver—obesity	0.000248	0.00147	CbGeAlD
Bosutinib—Malaise—Bupropion—obesity	0.000248	0.0016	CcSEcCtD
Bosutinib—CSNK1A1—adrenal gland—obesity	0.000247	0.00146	CbGeAlD
Bosutinib—MAP4K2—endocrine gland—obesity	0.000247	0.00146	CbGeAlD
Bosutinib—MAP2K2—pituitary gland—obesity	0.000247	0.00146	CbGeAlD
Bosutinib—ULK3—pituitary gland—obesity	0.000247	0.00146	CbGeAlD
Bosutinib—EPHB4—cardiovascular system—obesity	0.000246	0.00146	CbGeAlD
Bosutinib—Leukopenia—Bupropion—obesity	0.000246	0.00159	CcSEcCtD
Bosutinib—ERBB3—adipose tissue—obesity	0.000246	0.00146	CbGeAlD
Bosutinib—CSF1R—respiratory system—obesity	0.000246	0.00145	CbGeAlD
Bosutinib—MAP2K2—adipose tissue—obesity	0.000245	0.00145	CbGeAlD
Bosutinib—ULK3—adipose tissue—obesity	0.000245	0.00145	CbGeAlD
Bosutinib—CAMK1D—liver—obesity	0.000245	0.00145	CbGeAlD
Bosutinib—HCK—adrenal gland—obesity	0.000245	0.00145	CbGeAlD
Bosutinib—CLK1—adrenal gland—obesity	0.000245	0.00145	CbGeAlD
Bosutinib—PTK2B—digestive system—obesity	0.000244	0.00144	CbGeAlD
Bosutinib—ABL2—adrenal gland—obesity	0.000244	0.00144	CbGeAlD
Bosutinib—MAP3K2—adipose tissue—obesity	0.000244	0.00144	CbGeAlD
Bosutinib—ERBB4—endocrine gland—obesity	0.000243	0.00144	CbGeAlD
Bosutinib—STK24—liver—obesity	0.000243	0.00144	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Orlistat—obesity	0.000242	0.00156	CcSEcCtD
Bosutinib—MAP3K7—pituitary gland—obesity	0.000242	0.00144	CbGeAlD
Bosutinib—Bronchitis—Topiramate—obesity	0.000242	0.00156	CcSEcCtD
Bosutinib—EPHA2—cardiovascular system—obesity	0.000242	0.00143	CbGeAlD
Bosutinib—MAP3K7—adipose tissue—obesity	0.000241	0.00143	CbGeAlD
Bosutinib—FYN—cardiovascular system—obesity	0.000241	0.00143	CbGeAlD
Bosutinib—Abdominal discomfort—Topiramate—obesity	0.000241	0.00156	CcSEcCtD
Bosutinib—CAMK2G—adrenal gland—obesity	0.000241	0.00143	CbGeAlD
Bosutinib—BMP2K—adrenal gland—obesity	0.000241	0.00143	CbGeAlD
Bosutinib—ROCK1—endocrine gland—obesity	0.00024	0.00142	CbGeAlD
Bosutinib—CSNK1E—digestive system—obesity	0.00024	0.00142	CbGeAlD
Bosutinib—Cough—Bupropion—obesity	0.00024	0.00155	CcSEcCtD
Bosutinib—TBK1—pituitary gland—obesity	0.00024	0.00142	CbGeAlD
Bosutinib—PTK2—pituitary gland—obesity	0.00024	0.00142	CbGeAlD
Bosutinib—Pancytopenia—Topiramate—obesity	0.000239	0.00154	CcSEcCtD
Bosutinib—TBK1—adipose tissue—obesity	0.000239	0.00141	CbGeAlD
Bosutinib—PTK2—adipose tissue—obesity	0.000239	0.00141	CbGeAlD
Bosutinib—LRRK2—adrenal gland—obesity	0.000239	0.00141	CbGeAlD
Bosutinib—YES1—adrenal cortex—obesity	0.000239	0.00141	CbGeAlD
Bosutinib—EGFR—adrenal gland—obesity	0.000238	0.00141	CbGeAlD
Bosutinib—MAP3K3—cardiovascular system—obesity	0.000236	0.0014	CbGeAlD
Bosutinib—TAOK3—adrenal cortex—obesity	0.000236	0.00139	CbGeAlD
Bosutinib—Neutropenia—Topiramate—obesity	0.000235	0.00152	CcSEcCtD
Bosutinib—FER—liver—obesity	0.000235	0.00139	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Sibutramine—obesity	0.000235	0.00151	CcSEcCtD
Bosutinib—Arthralgia—Bupropion—obesity	0.000234	0.00151	CcSEcCtD
Bosutinib—Chest pain—Bupropion—obesity	0.000234	0.00151	CcSEcCtD
Bosutinib—Myalgia—Bupropion—obesity	0.000234	0.00151	CcSEcCtD
Bosutinib—IRAK1—adipose tissue—obesity	0.000234	0.00139	CbGeAlD
Bosutinib—Upper respiratory tract infection—Topiramate—obesity	0.000234	0.00151	CcSEcCtD
Bosutinib—LYN—liver—obesity	0.000234	0.00138	CbGeAlD
Bosutinib—BMPR2—endocrine gland—obesity	0.000233	0.00138	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.000233	0.0015	CcSEcCtD
Bosutinib—PTK2B—adrenal gland—obesity	0.000233	0.00138	CbGeAlD
Bosutinib—ERBB3—digestive system—obesity	0.000232	0.00137	CbGeAlD
Bosutinib—STK36—endocrine gland—obesity	0.000231	0.00137	CbGeAlD
Bosutinib—Discomfort—Bupropion—obesity	0.000231	0.00149	CcSEcCtD
Bosutinib—Decreased appetite—Orlistat—obesity	0.000231	0.00149	CcSEcCtD
Bosutinib—ULK3—digestive system—obesity	0.000231	0.00137	CbGeAlD
Bosutinib—MAP2K2—digestive system—obesity	0.000231	0.00137	CbGeAlD
Bosutinib—PDGFRB—islet of Langerhans—obesity	0.000231	0.00137	CbGeAlD
Bosutinib—RPS6KB1—pituitary gland—obesity	0.000231	0.00137	CbGeAlD
Bosutinib—Gastrointestinal disorder—Orlistat—obesity	0.00023	0.00148	CcSEcCtD
Bosutinib—RPS6KB1—adipose tissue—obesity	0.00023	0.00136	CbGeAlD
Bosutinib—Dyspnoea—Sibutramine—obesity	0.00023	0.00148	CcSEcCtD
Bosutinib—Fatigue—Orlistat—obesity	0.000229	0.00148	CcSEcCtD
Bosutinib—FGR—pituitary gland—obesity	0.000229	0.00136	CbGeAlD
Bosutinib—BTK—liver—obesity	0.000229	0.00136	CbGeAlD
Bosutinib—MERTK—endocrine gland—obesity	0.000229	0.00135	CbGeAlD
Bosutinib—CSNK1E—adrenal gland—obesity	0.000229	0.00135	CbGeAlD
Bosutinib—AXL—pituitary gland—obesity	0.000228	0.00135	CbGeAlD
Bosutinib—LCK—adipose tissue—obesity	0.000228	0.00135	CbGeAlD
Bosutinib—FGR—adipose tissue—obesity	0.000228	0.00135	CbGeAlD
Bosutinib—Pain—Orlistat—obesity	0.000228	0.00147	CcSEcCtD
Bosutinib—AXL—adipose tissue—obesity	0.000227	0.00135	CbGeAlD
Bosutinib—Pneumonia—Topiramate—obesity	0.000226	0.00146	CcSEcCtD
Bosutinib—TNK2—liver—obesity	0.000226	0.00134	CbGeAlD
Bosutinib—SIK1—adrenal gland—obesity	0.000225	0.00133	CbGeAlD
Bosutinib—IRAK4—adrenal gland—obesity	0.000225	0.00133	CbGeAlD
Bosutinib—TBK1—digestive system—obesity	0.000225	0.00133	CbGeAlD
Bosutinib—PTK2—digestive system—obesity	0.000225	0.00133	CbGeAlD
Bosutinib—MAP4K4—endocrine gland—obesity	0.000225	0.00133	CbGeAlD
Bosutinib—Anaphylactic shock—Bupropion—obesity	0.000225	0.00145	CcSEcCtD
Bosutinib—Oedema—Bupropion—obesity	0.000225	0.00145	CcSEcCtD
Bosutinib—Infestation NOS—Topiramate—obesity	0.000224	0.00145	CcSEcCtD
Bosutinib—Infestation—Topiramate—obesity	0.000224	0.00145	CcSEcCtD
Bosutinib—Decreased appetite—Sibutramine—obesity	0.000224	0.00144	CcSEcCtD
Bosutinib—Infection—Bupropion—obesity	0.000223	0.00144	CcSEcCtD
Bosutinib—BCR—endocrine gland—obesity	0.000223	0.00132	CbGeAlD
Bosutinib—EPHA4—adrenal gland—obesity	0.000223	0.00132	CbGeAlD
Bosutinib—MAP4K2—liver—obesity	0.000222	0.00132	CbGeAlD
Bosutinib—Gastrointestinal disorder—Sibutramine—obesity	0.000222	0.00143	CcSEcCtD
Bosutinib—MAP3K12—endocrine gland—obesity	0.000221	0.00131	CbGeAlD
Bosutinib—Renal failure—Topiramate—obesity	0.00022	0.00142	CcSEcCtD
Bosutinib—Pain—Sibutramine—obesity	0.00022	0.00142	CcSEcCtD
Bosutinib—MAP2K2—adrenal gland—obesity	0.00022	0.0013	CbGeAlD
Bosutinib—ULK3—adrenal gland—obesity	0.00022	0.0013	CbGeAlD
Bosutinib—Nervous system disorder—Bupropion—obesity	0.00022	0.00142	CcSEcCtD
Bosutinib—Thrombocytopenia—Bupropion—obesity	0.00022	0.00142	CcSEcCtD
Bosutinib—SLK—pituitary gland—obesity	0.00022	0.0013	CbGeAlD
Bosutinib—STK3—liver—obesity	0.000219	0.0013	CbGeAlD
Bosutinib—Feeling abnormal—Orlistat—obesity	0.000219	0.00141	CcSEcCtD
Bosutinib—SLK—adipose tissue—obesity	0.000219	0.0013	CbGeAlD
Bosutinib—MAP3K2—adrenal gland—obesity	0.000219	0.00129	CbGeAlD
Bosutinib—EPHB4—pituitary gland—obesity	0.000218	0.00129	CbGeAlD
Bosutinib—Skin disorder—Bupropion—obesity	0.000218	0.00141	CcSEcCtD
Bosutinib—PDGFRB—respiratory system—obesity	0.000218	0.00129	CbGeAlD
Bosutinib—Gastrointestinal pain—Orlistat—obesity	0.000218	0.0014	CcSEcCtD
Bosutinib—EPHB4—adipose tissue—obesity	0.000217	0.00129	CbGeAlD
Bosutinib—MAP2K1—endocrine gland—obesity	0.000217	0.00128	CbGeAlD
Bosutinib—STK35—endocrine gland—obesity	0.000217	0.00128	CbGeAlD
Bosutinib—MAP3K7—adrenal gland—obesity	0.000217	0.00128	CbGeAlD
Bosutinib—ROCK1—liver—obesity	0.000217	0.00128	CbGeAlD
Bosutinib—RPS6KB1—digestive system—obesity	0.000216	0.00128	CbGeAlD
Bosutinib—STK10—cardiovascular system—obesity	0.000216	0.00128	CbGeAlD
Bosutinib—CSK—endocrine gland—obesity	0.000215	0.00128	CbGeAlD
Bosutinib—TAOK3—cardiovascular system—obesity	0.000215	0.00127	CbGeAlD
Bosutinib—FGR—digestive system—obesity	0.000215	0.00127	CbGeAlD
Bosutinib—PTK2—adrenal gland—obesity	0.000214	0.00127	CbGeAlD
Bosutinib—TBK1—adrenal gland—obesity	0.000214	0.00127	CbGeAlD
Bosutinib—CSNK1A1—endocrine gland—obesity	0.000214	0.00127	CbGeAlD
Bosutinib—EPHA2—pituitary gland—obesity	0.000214	0.00127	CbGeAlD
Bosutinib—FYN—pituitary gland—obesity	0.000214	0.00126	CbGeAlD
Bosutinib—EPHA2—adipose tissue—obesity	0.000213	0.00126	CbGeAlD
Bosutinib—FYN—adipose tissue—obesity	0.000213	0.00126	CbGeAlD
Bosutinib—HCK—endocrine gland—obesity	0.000213	0.00126	CbGeAlD
Bosutinib—CLK1—endocrine gland—obesity	0.000213	0.00126	CbGeAlD
Bosutinib—Feeling abnormal—Sibutramine—obesity	0.000212	0.00137	CcSEcCtD
Bosutinib—Urticaria—Orlistat—obesity	0.000211	0.00136	CcSEcCtD
Bosutinib—MAP2K5—adrenal cortex—obesity	0.000211	0.00125	CbGeAlD
Bosutinib—Gastrointestinal pain—Sibutramine—obesity	0.000211	0.00136	CcSEcCtD
Bosutinib—Abdominal pain—Orlistat—obesity	0.00021	0.00136	CcSEcCtD
Bosutinib—Body temperature increased—Orlistat—obesity	0.00021	0.00136	CcSEcCtD
Bosutinib—BMPR2—liver—obesity	0.00021	0.00125	CbGeAlD
Bosutinib—IRAK1—adrenal gland—obesity	0.00021	0.00124	CbGeAlD
Bosutinib—SRC—cardiovascular system—obesity	0.000209	0.00124	CbGeAlD
Bosutinib—Agranulocytosis—Topiramate—obesity	0.000209	0.00135	CcSEcCtD
Bosutinib—CAMK2G—endocrine gland—obesity	0.000209	0.00124	CbGeAlD
Bosutinib—BMP2K—endocrine gland—obesity	0.000209	0.00124	CbGeAlD
Bosutinib—MAP4K5—pituitary gland—obesity	0.000209	0.00124	CbGeAlD
Bosutinib—MAP3K3—pituitary gland—obesity	0.000209	0.00124	CbGeAlD
Bosutinib—STK36—liver—obesity	0.000209	0.00124	CbGeAlD
Bosutinib—MAP3K3—adipose tissue—obesity	0.000208	0.00123	CbGeAlD
Bosutinib—MAP4K5—adipose tissue—obesity	0.000208	0.00123	CbGeAlD
Bosutinib—LRRK2—endocrine gland—obesity	0.000207	0.00123	CbGeAlD
Bosutinib—MERTK—liver—obesity	0.000206	0.00122	CbGeAlD
Bosutinib—CSF1R—adrenal cortex—obesity	0.000206	0.00122	CbGeAlD
Bosutinib—RPS6KB1—adrenal gland—obesity	0.000206	0.00122	CbGeAlD
Bosutinib—ABL1—islet of Langerhans—obesity	0.000206	0.00122	CbGeAlD
Bosutinib—LCK—adrenal gland—obesity	0.000205	0.00121	CbGeAlD
Bosutinib—FGR—adrenal gland—obesity	0.000205	0.00121	CbGeAlD
Bosutinib—Urticaria—Sibutramine—obesity	0.000205	0.00132	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Bupropion—obesity	0.000205	0.00132	CcSEcCtD
Bosutinib—EPHB4—digestive system—obesity	0.000205	0.00121	CbGeAlD
Bosutinib—AXL—adrenal gland—obesity	0.000204	0.00121	CbGeAlD
Bosutinib—Abdominal pain—Sibutramine—obesity	0.000204	0.00131	CcSEcCtD
Bosutinib—Body temperature increased—Sibutramine—obesity	0.000204	0.00131	CcSEcCtD
Bosutinib—MAP4K4—liver—obesity	0.000202	0.0012	CbGeAlD
Bosutinib—PTK2B—endocrine gland—obesity	0.000202	0.00119	CbGeAlD
Bosutinib—Hepatitis—Topiramate—obesity	0.000201	0.0013	CcSEcCtD
Bosutinib—BCR—liver—obesity	0.000201	0.00119	CbGeAlD
Bosutinib—NUAK2—liver—obesity	0.000201	0.00119	CbGeAlD
Bosutinib—EPHA2—digestive system—obesity	0.000201	0.00119	CbGeAlD
Bosutinib—FYN—digestive system—obesity	0.0002	0.00119	CbGeAlD
Bosutinib—Dyspnoea—Bupropion—obesity	0.0002	0.00129	CcSEcCtD
Bosutinib—MAP3K12—liver—obesity	0.0002	0.00118	CbGeAlD
Bosutinib—Urinary tract disorder—Topiramate—obesity	0.000199	0.00128	CcSEcCtD
Bosutinib—CSNK1E—endocrine gland—obesity	0.000198	0.00117	CbGeAlD
Bosutinib—Oedema peripheral—Topiramate—obesity	0.000198	0.00128	CcSEcCtD
Bosutinib—Connective tissue disorder—Topiramate—obesity	0.000198	0.00128	CcSEcCtD
Bosutinib—Urethral disorder—Topiramate—obesity	0.000197	0.00127	CcSEcCtD
Bosutinib—SLK—adrenal gland—obesity	0.000196	0.00116	CbGeAlD
Bosutinib—MAP2K1—liver—obesity	0.000196	0.00116	CbGeAlD
Bosutinib—STK35—liver—obesity	0.000196	0.00116	CbGeAlD
Bosutinib—SIK1—endocrine gland—obesity	0.000195	0.00116	CbGeAlD
Bosutinib—Decreased appetite—Bupropion—obesity	0.000195	0.00126	CcSEcCtD
Bosutinib—EPHB4—adrenal gland—obesity	0.000195	0.00115	CbGeAlD
Bosutinib—CSK—liver—obesity	0.000194	0.00115	CbGeAlD
Bosutinib—ABL1—respiratory system—obesity	0.000194	0.00115	CbGeAlD
Bosutinib—Gastrointestinal disorder—Bupropion—obesity	0.000194	0.00125	CcSEcCtD
Bosutinib—Fatigue—Bupropion—obesity	0.000194	0.00125	CcSEcCtD
Bosutinib—EPHA4—endocrine gland—obesity	0.000193	0.00114	CbGeAlD
Bosutinib—CSNK1A1—liver—obesity	0.000193	0.00114	CbGeAlD
Bosutinib—YES1—pituitary gland—obesity	0.000193	0.00114	CbGeAlD
Bosutinib—MAP2K5—cardiovascular system—obesity	0.000193	0.00114	CbGeAlD
Bosutinib—YES1—adipose tissue—obesity	0.000192	0.00114	CbGeAlD
Bosutinib—Pain—Bupropion—obesity	0.000192	0.00124	CcSEcCtD
Bosutinib—HCK—liver—obesity	0.000192	0.00114	CbGeAlD
Bosutinib—CLK1—liver—obesity	0.000192	0.00114	CbGeAlD
Bosutinib—ERBB3—endocrine gland—obesity	0.000191	0.00113	CbGeAlD
Bosutinib—EPHA2—adrenal gland—obesity	0.000191	0.00113	CbGeAlD
Bosutinib—MAP2K2—endocrine gland—obesity	0.000191	0.00113	CbGeAlD
Bosutinib—ULK3—endocrine gland—obesity	0.000191	0.00113	CbGeAlD
Bosutinib—Asthenia—Orlistat—obesity	0.000191	0.00123	CcSEcCtD
Bosutinib—FYN—adrenal gland—obesity	0.000191	0.00113	CbGeAlD
Bosutinib—ABL2—liver—obesity	0.000191	0.00113	CbGeAlD
Bosutinib—Erythema multiforme—Topiramate—obesity	0.00019	0.00123	CcSEcCtD
Bosutinib—TAOK3—pituitary gland—obesity	0.00019	0.00113	CbGeAlD
Bosutinib—STK10—adipose tissue—obesity	0.00019	0.00113	CbGeAlD
Bosutinib—MAP3K2—endocrine gland—obesity	0.00019	0.00112	CbGeAlD
Bosutinib—TAOK3—adipose tissue—obesity	0.00019	0.00112	CbGeAlD
Bosutinib—Pruritus—Orlistat—obesity	0.000188	0.00121	CcSEcCtD
Bosutinib—CAMK2G—liver—obesity	0.000188	0.00111	CbGeAlD
Bosutinib—BMP2K—liver—obesity	0.000188	0.00111	CbGeAlD
Bosutinib—CSF1R—cardiovascular system—obesity	0.000188	0.00111	CbGeAlD
Bosutinib—Tinnitus—Topiramate—obesity	0.000188	0.00121	CcSEcCtD
Bosutinib—Cardiac disorder—Topiramate—obesity	0.000187	0.00121	CcSEcCtD
Bosutinib—LRRK2—liver—obesity	0.000187	0.0011	CbGeAlD
Bosutinib—MAP3K3—adrenal gland—obesity	0.000186	0.0011	CbGeAlD
Bosutinib—MAP4K5—adrenal gland—obesity	0.000186	0.0011	CbGeAlD
Bosutinib—EGFR—liver—obesity	0.000186	0.0011	CbGeAlD
Bosutinib—TBK1—endocrine gland—obesity	0.000186	0.0011	CbGeAlD
Bosutinib—PTK2—endocrine gland—obesity	0.000186	0.0011	CbGeAlD
Bosutinib—Feeling abnormal—Bupropion—obesity	0.000185	0.00119	CcSEcCtD
Bosutinib—Asthenia—Sibutramine—obesity	0.000185	0.00119	CcSEcCtD
Bosutinib—SRC—adipose tissue—obesity	0.000185	0.00109	CbGeAlD
Bosutinib—Gastrointestinal pain—Bupropion—obesity	0.000184	0.00118	CcSEcCtD
Bosutinib—PDGFRB—adrenal cortex—obesity	0.000183	0.00108	CbGeAlD
Bosutinib—Pruritus—Sibutramine—obesity	0.000182	0.00118	CcSEcCtD
Bosutinib—Diarrhoea—Orlistat—obesity	0.000182	0.00117	CcSEcCtD
Bosutinib—Immune system disorder—Topiramate—obesity	0.000182	0.00117	CcSEcCtD
Bosutinib—PTK2B—liver—obesity	0.000182	0.00108	CbGeAlD
Bosutinib—Mediastinal disorder—Topiramate—obesity	0.000181	0.00117	CcSEcCtD
Bosutinib—YES1—digestive system—obesity	0.000181	0.00107	CbGeAlD
Bosutinib—STK10—digestive system—obesity	0.000179	0.00106	CbGeAlD
Bosutinib—CSNK1E—liver—obesity	0.000179	0.00106	CbGeAlD
Bosutinib—RPS6KB1—endocrine gland—obesity	0.000179	0.00106	CbGeAlD
Bosutinib—TAOK3—digestive system—obesity	0.000178	0.00106	CbGeAlD
Bosutinib—Urticaria—Bupropion—obesity	0.000178	0.00115	CcSEcCtD
Bosutinib—FGR—endocrine gland—obesity	0.000178	0.00105	CbGeAlD
Bosutinib—Body temperature increased—Bupropion—obesity	0.000177	0.00114	CcSEcCtD
Bosutinib—Abdominal pain—Bupropion—obesity	0.000177	0.00114	CcSEcCtD
Bosutinib—AXL—endocrine gland—obesity	0.000177	0.00105	CbGeAlD
Bosutinib—Diarrhoea—Sibutramine—obesity	0.000176	0.00114	CcSEcCtD
Bosutinib—SIK1—liver—obesity	0.000176	0.00104	CbGeAlD
Bosutinib—IRAK4—liver—obesity	0.000176	0.00104	CbGeAlD
Bosutinib—Dizziness—Orlistat—obesity	0.000176	0.00114	CcSEcCtD
Bosutinib—Malnutrition—Topiramate—obesity	0.000175	0.00113	CcSEcCtD
Bosutinib—SRC—digestive system—obesity	0.000174	0.00103	CbGeAlD
Bosutinib—ERBB3—liver—obesity	0.000173	0.00102	CbGeAlD
Bosutinib—YES1—adrenal gland—obesity	0.000172	0.00102	CbGeAlD
Bosutinib—MAP2K2—liver—obesity	0.000172	0.00102	CbGeAlD
Bosutinib—ULK3—liver—obesity	0.000172	0.00102	CbGeAlD
Bosutinib—Dysgeusia—Topiramate—obesity	0.000172	0.00111	CcSEcCtD
Bosutinib—MAP3K2—liver—obesity	0.000171	0.00101	CbGeAlD
Bosutinib—STK10—adrenal gland—obesity	0.000171	0.00101	CbGeAlD
Bosutinib—MAP2K5—pituitary gland—obesity	0.000171	0.00101	CbGeAlD
Bosutinib—Dizziness—Sibutramine—obesity	0.00017	0.0011	CcSEcCtD
Bosutinib—TAOK3—adrenal gland—obesity	0.00017	0.00101	CbGeAlD
Bosutinib—MAP2K5—adipose tissue—obesity	0.00017	0.00101	CbGeAlD
Bosutinib—Back pain—Topiramate—obesity	0.00017	0.00109	CcSEcCtD
Bosutinib—MAP3K7—liver—obesity	0.000169	0.001	CbGeAlD
Bosutinib—Vomiting—Orlistat—obesity	0.000169	0.00109	CcSEcCtD
Bosutinib—EPHB4—endocrine gland—obesity	0.000169	0.001	CbGeAlD
Bosutinib—Rash—Orlistat—obesity	0.000168	0.00108	CcSEcCtD
Bosutinib—Dermatitis—Orlistat—obesity	0.000168	0.00108	CcSEcCtD
Bosutinib—PTK2—liver—obesity	0.000167	0.000991	CbGeAlD
Bosutinib—TBK1—liver—obesity	0.000167	0.000991	CbGeAlD
Bosutinib—PDGFRB—cardiovascular system—obesity	0.000167	0.000988	CbGeAlD
Bosutinib—Headache—Orlistat—obesity	0.000167	0.00108	CcSEcCtD
Bosutinib—CSF1R—pituitary gland—obesity	0.000167	0.000986	CbGeAlD
Bosutinib—CSF1R—adipose tissue—obesity	0.000166	0.000982	CbGeAlD
Bosutinib—EPHA2—endocrine gland—obesity	0.000166	0.000982	CbGeAlD
Bosutinib—SRC—adrenal gland—obesity	0.000166	0.000981	CbGeAlD
Bosutinib—FYN—endocrine gland—obesity	0.000165	0.00098	CbGeAlD
Bosutinib—IRAK1—liver—obesity	0.000164	0.000972	CbGeAlD
Bosutinib—Vomiting—Sibutramine—obesity	0.000164	0.00106	CcSEcCtD
Bosutinib—ABL1—adrenal cortex—obesity	0.000163	0.000964	CbGeAlD
Bosutinib—Ill-defined disorder—Topiramate—obesity	0.000163	0.00105	CcSEcCtD
Bosutinib—Rash—Sibutramine—obesity	0.000162	0.00105	CcSEcCtD
Bosutinib—Dermatitis—Sibutramine—obesity	0.000162	0.00105	CcSEcCtD
Bosutinib—Anaemia—Topiramate—obesity	0.000162	0.00105	CcSEcCtD
Bosutinib—MAP4K5—endocrine gland—obesity	0.000162	0.000958	CbGeAlD
Bosutinib—MAP3K3—endocrine gland—obesity	0.000162	0.000958	CbGeAlD
Bosutinib—Headache—Sibutramine—obesity	0.000161	0.00104	CcSEcCtD
Bosutinib—Asthenia—Bupropion—obesity	0.000161	0.00104	CcSEcCtD
Bosutinib—RPS6KB1—liver—obesity	0.000161	0.000954	CbGeAlD
Bosutinib—FGR—liver—obesity	0.00016	0.000948	CbGeAlD
Bosutinib—LCK—liver—obesity	0.00016	0.000948	CbGeAlD
Bosutinib—AXL—liver—obesity	0.000159	0.000944	CbGeAlD
Bosutinib—Pruritus—Bupropion—obesity	0.000159	0.00102	CcSEcCtD
Bosutinib—Nausea—Orlistat—obesity	0.000158	0.00102	CcSEcCtD
Bosutinib—Malaise—Topiramate—obesity	0.000158	0.00102	CcSEcCtD
Bosutinib—Leukopenia—Topiramate—obesity	0.000157	0.00101	CcSEcCtD
Bosutinib—CSF1R—digestive system—obesity	0.000156	0.000924	CbGeAlD
Bosutinib—Diarrhoea—Bupropion—obesity	0.000154	0.000991	CcSEcCtD
Bosutinib—SLK—liver—obesity	0.000153	0.000909	CbGeAlD
Bosutinib—Nausea—Sibutramine—obesity	0.000153	0.000987	CcSEcCtD
Bosutinib—Cough—Topiramate—obesity	0.000153	0.000987	CcSEcCtD
Bosutinib—MAP2K5—adrenal gland—obesity	0.000152	0.000902	CbGeAlD
Bosutinib—EPHB4—liver—obesity	0.000152	0.000902	CbGeAlD
Bosutinib—EPHA2—liver—obesity	0.000149	0.000885	CbGeAlD
Bosutinib—YES1—endocrine gland—obesity	0.000149	0.000884	CbGeAlD
Bosutinib—Myalgia—Topiramate—obesity	0.000149	0.000963	CcSEcCtD
Bosutinib—Chest pain—Topiramate—obesity	0.000149	0.000963	CcSEcCtD
Bosutinib—Arthralgia—Topiramate—obesity	0.000149	0.000963	CcSEcCtD
Bosutinib—FYN—liver—obesity	0.000149	0.000883	CbGeAlD
Bosutinib—CSF1R—adrenal gland—obesity	0.000149	0.000881	CbGeAlD
Bosutinib—ABL1—cardiovascular system—obesity	0.000149	0.00088	CbGeAlD
Bosutinib—Dizziness—Bupropion—obesity	0.000148	0.000958	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	0.000148	0.000956	CcSEcCtD
Bosutinib—STK10—endocrine gland—obesity	0.000148	0.000876	CbGeAlD
Bosutinib—PDGFRB—pituitary gland—obesity	0.000148	0.000874	CbGeAlD
Bosutinib—TAOK3—endocrine gland—obesity	0.000147	0.000873	CbGeAlD
Bosutinib—Discomfort—Topiramate—obesity	0.000147	0.000951	CcSEcCtD
Bosutinib—PDGFRB—adipose tissue—obesity	0.000147	0.000871	CbGeAlD
Bosutinib—MAP4K5—liver—obesity	0.000146	0.000863	CbGeAlD
Bosutinib—MAP3K3—liver—obesity	0.000146	0.000863	CbGeAlD
Bosutinib—SRC—endocrine gland—obesity	0.000144	0.000851	CbGeAlD
Bosutinib—Oedema—Topiramate—obesity	0.000143	0.000923	CcSEcCtD
Bosutinib—Vomiting—Bupropion—obesity	0.000143	0.000921	CcSEcCtD
Bosutinib—Infection—Topiramate—obesity	0.000142	0.000917	CcSEcCtD
Bosutinib—Rash—Bupropion—obesity	0.000142	0.000913	CcSEcCtD
Bosutinib—Dermatitis—Bupropion—obesity	0.000141	0.000912	CcSEcCtD
Bosutinib—Headache—Bupropion—obesity	0.000141	0.000907	CcSEcCtD
Bosutinib—Nervous system disorder—Topiramate—obesity	0.00014	0.000905	CcSEcCtD
Bosutinib—Thrombocytopenia—Topiramate—obesity	0.00014	0.000904	CcSEcCtD
Bosutinib—Skin disorder—Topiramate—obesity	0.000139	0.000896	CcSEcCtD
Bosutinib—PDGFRB—digestive system—obesity	0.000138	0.00082	CbGeAlD
Bosutinib—YES1—liver—obesity	0.000135	0.000797	CbGeAlD
Bosutinib—STK10—liver—obesity	0.000133	0.00079	CbGeAlD
Bosutinib—Nausea—Bupropion—obesity	0.000133	0.00086	CcSEcCtD
Bosutinib—TAOK3—liver—obesity	0.000133	0.000787	CbGeAlD
Bosutinib—MAP2K5—endocrine gland—obesity	0.000132	0.000783	CbGeAlD
Bosutinib—PDGFRB—adrenal gland—obesity	0.000132	0.000781	CbGeAlD
Bosutinib—ABL1—pituitary gland—obesity	0.000132	0.000779	CbGeAlD
Bosutinib—ABL1—adipose tissue—obesity	0.000131	0.000776	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Topiramate—obesity	0.00013	0.000841	CcSEcCtD
Bosutinib—SRC—liver—obesity	0.00013	0.000767	CbGeAlD
Bosutinib—CSF1R—endocrine gland—obesity	0.000129	0.000764	CbGeAlD
Bosutinib—Dyspnoea—Topiramate—obesity	0.000128	0.000823	CcSEcCtD
Bosutinib—Decreased appetite—Topiramate—obesity	0.000124	0.000802	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Topiramate—obesity	0.000123	0.000797	CcSEcCtD
Bosutinib—ABL1—digestive system—obesity	0.000123	0.000731	CbGeAlD
Bosutinib—Fatigue—Topiramate—obesity	0.000123	0.000796	CcSEcCtD
Bosutinib—Pain—Topiramate—obesity	0.000122	0.000789	CcSEcCtD
Bosutinib—MAP2K5—liver—obesity	0.000119	0.000706	CbGeAlD
Bosutinib—Feeling abnormal—Topiramate—obesity	0.000118	0.00076	CcSEcCtD
Bosutinib—ABL1—adrenal gland—obesity	0.000118	0.000696	CbGeAlD
Bosutinib—Gastrointestinal pain—Topiramate—obesity	0.000117	0.000755	CcSEcCtD
Bosutinib—CSF1R—liver—obesity	0.000116	0.000689	CbGeAlD
Bosutinib—PDGFRB—endocrine gland—obesity	0.000114	0.000677	CbGeAlD
Bosutinib—Urticaria—Topiramate—obesity	0.000114	0.000733	CcSEcCtD
Bosutinib—Abdominal pain—Topiramate—obesity	0.000113	0.000729	CcSEcCtD
Bosutinib—Body temperature increased—Topiramate—obesity	0.000113	0.000729	CcSEcCtD
Bosutinib—PDGFRB—liver—obesity	0.000103	0.000611	CbGeAlD
Bosutinib—Asthenia—Topiramate—obesity	0.000103	0.000662	CcSEcCtD
Bosutinib—ABL1—endocrine gland—obesity	0.000102	0.000604	CbGeAlD
Bosutinib—Pruritus—Topiramate—obesity	0.000101	0.000653	CcSEcCtD
Bosutinib—Diarrhoea—Topiramate—obesity	9.79e-05	0.000631	CcSEcCtD
Bosutinib—Dizziness—Topiramate—obesity	9.46e-05	0.00061	CcSEcCtD
Bosutinib—ABL1—liver—obesity	9.19e-05	0.000544	CbGeAlD
Bosutinib—Vomiting—Topiramate—obesity	9.09e-05	0.000587	CcSEcCtD
Bosutinib—Rash—Topiramate—obesity	9.02e-05	0.000582	CcSEcCtD
Bosutinib—Dermatitis—Topiramate—obesity	9.01e-05	0.000581	CcSEcCtD
Bosutinib—Headache—Topiramate—obesity	8.96e-05	0.000578	CcSEcCtD
Bosutinib—Nausea—Topiramate—obesity	8.5e-05	0.000548	CcSEcCtD
Bosutinib—ABCB1—islet of Langerhans—obesity	6.39e-05	0.000378	CbGeAlD
Bosutinib—ABCB1—respiratory system—obesity	6.04e-05	0.000357	CbGeAlD
Bosutinib—CYP3A4—digestive system—obesity	5.42e-05	0.000321	CbGeAlD
Bosutinib—ABCB1—adrenal cortex—obesity	5.07e-05	0.0003	CbGeAlD
Bosutinib—ABCB1—cardiovascular system—obesity	4.62e-05	0.000274	CbGeAlD
Bosutinib—CYP3A4—endocrine gland—obesity	4.48e-05	0.000265	CbGeAlD
Bosutinib—ABCB1—pituitary gland—obesity	4.09e-05	0.000242	CbGeAlD
Bosutinib—ABCB1—adipose tissue—obesity	4.08e-05	0.000241	CbGeAlD
Bosutinib—CYP3A4—liver—obesity	4.04e-05	0.000239	CbGeAlD
Bosutinib—ABCB1—digestive system—obesity	3.84e-05	0.000227	CbGeAlD
Bosutinib—ABCB1—adrenal gland—obesity	3.66e-05	0.000216	CbGeAlD
Bosutinib—ABCB1—endocrine gland—obesity	3.17e-05	0.000188	CbGeAlD
Bosutinib—ABCB1—liver—obesity	2.86e-05	0.000169	CbGeAlD
Bosutinib—EGFR—Signaling Pathways—RHOA—obesity	5.72e-07	2.12e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SERPINE1—obesity	5.72e-07	2.12e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—PIK3CA—obesity	5.7e-07	2.12e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—APOB—obesity	5.7e-07	2.12e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—STAT3—obesity	5.69e-07	2.11e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—PIK3CA—obesity	5.67e-07	2.11e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—AKT1—obesity	5.67e-07	2.1e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL6—obesity	5.67e-07	2.1e-06	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—AKT1—obesity	5.66e-07	2.1e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3R1—obesity	5.66e-07	2.1e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NOS3—obesity	5.66e-07	2.1e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CPT1A—obesity	5.64e-07	2.09e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MYC—obesity	5.61e-07	2.08e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TGFB1—obesity	5.6e-07	2.08e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—PIK3CA—obesity	5.6e-07	2.08e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MMP9—obesity	5.59e-07	2.07e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TYK2—obesity	5.56e-07	2.06e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—STAT3—obesity	5.56e-07	2.06e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—POMC—obesity	5.54e-07	2.06e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NAMPT—obesity	5.53e-07	2.05e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—RHOA—obesity	5.51e-07	2.05e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—INS—obesity	5.51e-07	2.04e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL6—obesity	5.5e-07	2.04e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—LIPC—obesity	5.49e-07	2.04e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GCK—obesity	5.49e-07	2.04e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—PIK3CA—obesity	5.46e-07	2.03e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOC3—obesity	5.46e-07	2.03e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL6—obesity	5.46e-07	2.03e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3R1—obesity	5.46e-07	2.03e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NOS3—obesity	5.46e-07	2.03e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MMP9—obesity	5.46e-07	2.02e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—LPL—obesity	5.44e-07	2.02e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MAPK8—obesity	5.44e-07	2.02e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—AKT1—obesity	5.42e-07	2.01e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCL2—obesity	5.42e-07	2.01e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—PIK3CA—obesity	5.39e-07	2e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL6—obesity	5.37e-07	1.99e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MYC—obesity	5.36e-07	1.99e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—TGFB1—obesity	5.35e-07	1.98e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MMP9—obesity	5.34e-07	1.98e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—STAT3—obesity	5.33e-07	1.98e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IGF1—obesity	5.33e-07	1.98e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT2—obesity	5.32e-07	1.98e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GPX1—obesity	5.31e-07	1.97e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MAPK8—obesity	5.31e-07	1.97e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—AKT1—obesity	5.3e-07	1.97e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CETP—obesity	5.3e-07	1.97e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MYC—obesity	5.29e-07	1.96e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TGFB1—obesity	5.27e-07	1.96e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—PIK3CA—obesity	5.27e-07	1.95e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MMP9—obesity	5.26e-07	1.95e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL6—obesity	5.26e-07	1.95e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL6—obesity	5.26e-07	1.95e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SDC1—obesity	5.24e-07	1.95e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL6—obesity	5.24e-07	1.94e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PIK3CA—obesity	5.24e-07	1.94e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MMP9—obesity	5.23e-07	1.94e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—AKT1—obesity	5.23e-07	1.94e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CB—obesity	5.23e-07	1.94e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MTOR—obesity	5.23e-07	1.94e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK8—obesity	5.19e-07	1.93e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CD36—obesity	5.17e-07	1.92e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MYC—obesity	5.17e-07	1.92e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKR1C3—obesity	5.16e-07	1.91e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—TGFB1—obesity	5.15e-07	1.91e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—obesity	5.13e-07	1.9e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CD—obesity	5.12e-07	1.9e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK8—obesity	5.11e-07	1.9e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—obesity	5.11e-07	1.9e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—PIK3CA—obesity	5.09e-07	1.89e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK8—obesity	5.09e-07	1.89e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SCARB1—obesity	5.08e-07	1.88e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—AKT1—obesity	5.07e-07	1.88e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—obesity	5.07e-07	1.88e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SERPINE1—obesity	5.06e-07	1.88e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—obesity	5.05e-07	1.87e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MTOR—obesity	5.04e-07	1.87e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CB—obesity	5.04e-07	1.87e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—obesity	5.03e-07	1.87e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—obesity	5.02e-07	1.86e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PIK3CA—obesity	5.02e-07	1.86e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—STAT3—obesity	4.97e-07	1.84e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—obesity	4.96e-07	1.84e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—obesity	4.95e-07	1.84e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SREBF1—obesity	4.93e-07	1.83e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PIK3CA—obesity	4.93e-07	1.83e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TYK2—obesity	4.92e-07	1.83e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—STAT3—obesity	4.92e-07	1.83e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—MTHFR—obesity	4.9e-07	1.82e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RHOA—obesity	4.88e-07	1.81e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—obesity	4.85e-07	1.8e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—obesity	4.85e-07	1.8e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—STAT3—obesity	4.85e-07	1.8e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—obesity	4.84e-07	1.8e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—obesity	4.83e-07	1.79e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NOS3—obesity	4.83e-07	1.79e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3R1—obesity	4.83e-07	1.79e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARA—obesity	4.81e-07	1.78e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GOT2—obesity	4.79e-07	1.78e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—obesity	4.78e-07	1.77e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PIK3CA—obesity	4.76e-07	1.77e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—PIK3CA—obesity	4.75e-07	1.76e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—STAT3—obesity	4.75e-07	1.76e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—obesity	4.73e-07	1.76e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—obesity	4.71e-07	1.75e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—FASN—obesity	4.69e-07	1.74e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—STAT3—obesity	4.68e-07	1.74e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—obesity	4.68e-07	1.74e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—BCHE—obesity	4.67e-07	1.73e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—obesity	4.66e-07	1.73e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—obesity	4.66e-07	1.73e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AGT—obesity	4.66e-07	1.73e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—STAT3—obesity	4.65e-07	1.73e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—obesity	4.64e-07	1.72e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—obesity	4.63e-07	1.72e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—obesity	4.62e-07	1.71e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TGFB1—obesity	4.61e-07	1.71e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—obesity	4.57e-07	1.7e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—obesity	4.57e-07	1.7e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—APOE—obesity	4.56e-07	1.69e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—TGFB1—obesity	4.56e-07	1.69e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PIK3CA—obesity	4.55e-07	1.69e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—obesity	4.54e-07	1.69e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CAV1—obesity	4.52e-07	1.68e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—obesity	4.51e-07	1.67e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—APOA1—obesity	4.51e-07	1.67e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP2E1—obesity	4.51e-07	1.67e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—obesity	4.51e-07	1.67e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TGFB1—obesity	4.5e-07	1.67e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PIK3CA—obesity	4.49e-07	1.67e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—obesity	4.46e-07	1.66e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CB—obesity	4.46e-07	1.65e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MTOR—obesity	4.46e-07	1.65e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NQO1—obesity	4.46e-07	1.65e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—obesity	4.45e-07	1.65e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK8—obesity	4.42e-07	1.64e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—obesity	4.41e-07	1.64e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—obesity	4.41e-07	1.64e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TGFB1—obesity	4.4e-07	1.63e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PIK3CA—obesity	4.38e-07	1.63e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—obesity	4.38e-07	1.62e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—obesity	4.36e-07	1.62e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—obesity	4.34e-07	1.61e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TGFB1—obesity	4.33e-07	1.61e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—obesity	4.32e-07	1.6e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TGFB1—obesity	4.31e-07	1.6e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—obesity	4.3e-07	1.6e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—obesity	4.28e-07	1.59e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GCG—obesity	4.27e-07	1.59e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC2A4—obesity	4.27e-07	1.59e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK8—obesity	4.26e-07	1.58e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—obesity	4.22e-07	1.57e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYCS—obesity	4.22e-07	1.57e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—obesity	4.21e-07	1.56e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—PIK3CA—obesity	4.2e-07	1.56e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—obesity	4.16e-07	1.54e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GGT1—obesity	4.14e-07	1.54e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GOT1—obesity	4.14e-07	1.54e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CG—obesity	4.12e-07	1.53e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—obesity	4.1e-07	1.52e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NCOA1—obesity	4.08e-07	1.51e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—STAT3—obesity	4.04e-07	1.5e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—obesity	4.03e-07	1.5e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—obesity	4.03e-07	1.49e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—STK11—obesity	4.02e-07	1.49e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP19A1—obesity	4.02e-07	1.49e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARG—obesity	3.97e-07	1.47e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—obesity	3.97e-07	1.47e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PIK3CA—obesity	3.92e-07	1.46e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—POMC—obesity	3.92e-07	1.45e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—INS—obesity	3.9e-07	1.45e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—STAT3—obesity	3.89e-07	1.44e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—obesity	3.89e-07	1.44e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—obesity	3.88e-07	1.44e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PIK3CA—obesity	3.88e-07	1.44e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—obesity	3.88e-07	1.44e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—obesity	3.88e-07	1.44e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PIK3CA—obesity	3.83e-07	1.42e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK8—obesity	3.77e-07	1.4e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—obesity	3.75e-07	1.39e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PIK3CA—obesity	3.75e-07	1.39e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TGFB1—obesity	3.74e-07	1.39e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—COMT—obesity	3.74e-07	1.39e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—obesity	3.72e-07	1.38e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—obesity	3.72e-07	1.38e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PIK3CA—obesity	3.69e-07	1.37e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARGC1A—obesity	3.68e-07	1.37e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GNB3—obesity	3.68e-07	1.37e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PIK3CA—obesity	3.67e-07	1.36e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HMOX1—obesity	3.67e-07	1.36e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—obesity	3.67e-07	1.36e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CD—obesity	3.62e-07	1.34e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—obesity	3.62e-07	1.34e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TGFB1—obesity	3.61e-07	1.34e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GNAS—obesity	3.59e-07	1.33e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—obesity	3.58e-07	1.33e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ALB—obesity	3.57e-07	1.33e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOB—obesity	3.51e-07	1.3e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—obesity	3.47e-07	1.29e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—STAT3—obesity	3.45e-07	1.28e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—obesity	3.44e-07	1.28e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—obesity	3.43e-07	1.27e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3R1—obesity	3.42e-07	1.27e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—NOS3—obesity	3.42e-07	1.27e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—obesity	3.39e-07	1.26e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—LPL—obesity	3.35e-07	1.24e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—obesity	3.32e-07	1.23e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GPX1—obesity	3.27e-07	1.21e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—obesity	3.27e-07	1.21e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—obesity	3.25e-07	1.21e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—obesity	3.2e-07	1.19e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—obesity	3.2e-07	1.19e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TGFB1—obesity	3.19e-07	1.19e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CD36—obesity	3.19e-07	1.18e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CA—obesity	3.19e-07	1.18e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—obesity	3.17e-07	1.18e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CB—obesity	3.15e-07	1.17e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—obesity	3.13e-07	1.16e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—obesity	3.13e-07	1.16e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CA—obesity	3.07e-07	1.14e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—obesity	3.06e-07	1.14e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MTHFR—obesity	3.02e-07	1.12e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—obesity	3.01e-07	1.12e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—obesity	3e-07	1.11e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARA—obesity	2.96e-07	1.1e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AGT—obesity	2.87e-07	1.06e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—obesity	2.82e-07	1.05e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOE—obesity	2.81e-07	1.04e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CAV1—obesity	2.78e-07	1.03e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOA1—obesity	2.78e-07	1.03e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—obesity	2.72e-07	1.01e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CA—obesity	2.72e-07	1.01e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—obesity	2.6e-07	9.66e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CG—obesity	2.54e-07	9.41e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—obesity	2.51e-07	9.31e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARG—obesity	2.45e-07	9.09e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—POMC—obesity	2.41e-07	8.96e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—obesity	2.41e-07	8.93e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—INS—obesity	2.4e-07	8.91e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CD—obesity	2.23e-07	8.28e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—obesity	2.22e-07	8.24e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALB—obesity	2.2e-07	8.17e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3R1—obesity	2.11e-07	7.82e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NOS3—obesity	2.11e-07	7.82e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CB—obesity	1.94e-07	7.21e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—obesity	1.93e-07	7.15e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CA—obesity	1.92e-07	7.14e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—obesity	1.57e-07	5.83e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CA—obesity	1.18e-07	4.4e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—obesity	9.68e-08	3.59e-07	CbGpPWpGaD
